The JAK2 V617F mutation is the most prevalent driver mutation in myeloproliferative neoplasms (MPNs), and genetically engineered mouse models carrying this mutation are indispensable tools for studying MPN pathogenesis and evaluating targeted therapies. JAK2 V617F mouse gene mutation detection provides reliable genotyping confirmation, quantitative mutant allele burden measurement, and longitudinal disease monitoring for research colonies. This technical guide summarizes the principles, sample requirements, detection methods, and applications of JAK2 V617F testing in laboratory mice.
Technical Overview
JAK2 V617F is a gain-of-function point mutation in the Janus kinase 2 (JAK2) gene, corresponding to a G-to-T transversion (c.1849G>T) that substitutes phenylalanine for valine at codon 617 (p.Val617Phe) in the pseudokinase (JH2) domain. This substitution disrupts the autoinhibitory interaction between the JH2 and JH1 kinase domains, resulting in constitutive kinase activity and persistent activation of downstream JAK-STAT, PI3K/AKT, and MAPK signaling pathways. In humans, the mutation is present in over 95% of polycythemia vera cases and in a substantial proportion of essential thrombocythemia and primary myelofibrosis patients.
To model these myeloproliferative neoplasms, researchers have developed JAK2 V617F mouse models, including transgenic strains expressing the mutant human JAK2 allele and conditional knock-in strains in which the murine Jak2 V617F allele is activated in hematopoietic tissues by Cre recombinase (for example, Mx1-Cre or Vav-Cre systems). These mice reliably develop erythrocytosis, leukocytosis, splenomegaly, and progressive myelofibrosis, closely recapitulating the human disease spectrum. Accurate molecular detection of the JAK2 V617F allele is therefore essential for colony genotyping, confirming Cre-mediated recombination, quantifying mutant allele burden, and correlating genotype with hematologic phenotype.
Testing Samples
Tail Tissue and Ear Punch Biopsies
Tail snips (approximately 2 to 5 mm) and ear punch biopsies are the standard sample types for routine genotyping of neonatal or weanling mice. These samples yield sufficient genomic DNA for multiple PCR reactions and are collected during standard identification procedures, minimizing additional animal handling. Samples should be fresh or stored at -20°C or below if processing is delayed, and ethanol-preserved tissue is generally acceptable for most PCR-based assays.
Peripheral Blood
Peripheral blood collected from the tail vein, saphenous vein, or submandibular vein is suitable for quantitative monitoring of mutant allele burden in longitudinal studies. Small volumes (10 to 50 µL) are sufficient for allele-specific qPCR or droplet digital PCR. Serial blood sampling allows researchers to track clonal expansion or therapeutic response in the same animal over time, which reduces animal usage and improves statistical power.
Bone Marrow and Spleen Tissue
Bone marrow cells flushed from femurs and tibias, as well as splenic tissue, provide the most representative material for assessing hematopoietic mutant allele burden at endpoint analysis. These tissues are particularly valuable in transplantation experiments, competitive chimerism studies, and analyses of myelofibrosis progression. Fresh or frozen tissue, or purified genomic DNA extracted from these sources, can all be submitted for testing.
Purified Genomic DNA
High-quality genomic DNA extracted by the submitting laboratory is accepted provided that the concentration, purity (A260/A280 ratio between 1.7 and 2.0), and integrity meet assay requirements. A minimum of 50 to 100 ng of genomic DNA is typically recommended for most applications, although droplet digital PCR can deliver reliable results from substantially lower input amounts.
Testing Items
The JAK2 V617F mouse gene mutation detection service encompasses the following core testing items:
- Genotype identification: determination of wild-type homozygous (WT/WT), heterozygous (WT/V617F), and mutant homozygous (V617F/V617F) status for line maintenance and experimental group assignment.
- Cre-mediated recombination verification: confirmation of successful excision of the floxed STOP cassette in conditional knock-in alleles, distinguishing recombined from unrecombined alleles.
- Mutant allele burden quantification: measurement of the variant allele frequency (VAF), expressed as the percentage of the mutant allele relative to total Jak2 alleles, which serves as a molecular correlate of disease burden.
- Zygosity determination for transgenic lines: assessment of relative transgene copy number or integration status where applicable.
- Longitudinal monitoring: serial quantification of VAF to evaluate clonal dynamics, disease progression, and response to therapeutic interventions such as JAK inhibitors.
Testing Methods
Multiple complementary platforms are available, and the optimal method depends on the required sensitivity, throughput, and whether quantitative information is needed.
- Allele-specific PCR (AS-PCR): a rapid, cost-effective method that uses primers specific to the mutant or wild-type allele. It is well suited for routine genotyping of established colonies and delivers clear qualitative results, typically within one working day.
- Sanger sequencing: direct sequencing of the PCR-amplified exon 14 region provides unambiguous confirmation of the mutation and detects neighboring sequence variants. Its analytical sensitivity is approximately 15 to 20% variant allele fraction, making it appropriate for genotyping but not for low-level burden monitoring.
- Quantitative real-time PCR (qPCR): allele-specific hydrolysis probes enable measurement of mutant allele burden with a sensitivity of approximately 1% VAF. This is the standard method for longitudinal disease monitoring in JAK2 V617F mouse studies.
- Droplet digital PCR (ddPCR): partitioning of reactions into thousands of droplets allows absolute quantification of mutant and wild-type alleles without external standards. ddPCR achieves sensitivities of 0.1% VAF or lower and is the method of choice for detecting minimal residual disease and low-frequency clones.
- Next-generation sequencing (NGS): targeted amplicon or panel sequencing enables simultaneous detection of JAK2 V617F and co-occurring mutations (for example, in TET2, ASXL1, or CALR), supporting clonal hierarchy studies with sensitivities of approximately 1 to 5% VAF depending on depth of coverage.
Applications
JAK2 V617F mouse gene mutation detection supports a wide range of research applications:
- Myeloproliferative neoplasm research: characterization of disease initiation, clonal evolution, and progression from polycythemia-like phenotypes to myelofibrosis in mutant mouse models.
- Drug development and evaluation: pharmacodynamic assessment of JAK inhibitors (such as ruxolitinib fedratinib, and pacritinib) and novel therapeutic candidates, using mutant allele burden as a molecular endpoint.
- Hematopoiesis and stem cell biology: quantification of mutant hematopoietic stem cell contribution through competitive transplantation and chimerism assays.
- Colony management: routine genotyping of breeding colonies to confirm germline or conditional allele transmission and to allocate animals to experimental groups.
- Biomarker and companion diagnostic research: establishing the correlation between mutant allele dynamics and hematologic parameters such as hematocrit, leukocyte counts, and spleen size.
- Comparative oncology: investigation of cooperation between JAK2 V617F and additional genetic lesions in MPN transformation and leukemic progression.
FAQ
What is the detection sensitivity of each method?
Sanger sequencing reliably detects mutant alleles at approximately 15 to 20% VAF, qPCR reaches approximately 1% VAF, and ddPCR can detect mutant alleles at 0.1% VAF or lower. For routine genotyping, AS-PCR or Sanger sequencing is sufficient; for minimal residual disease or low-burden monitoring, ddPCR is recommended.
How much sample is required for testing?
A 2 to 5 mm tail snip, one ear punch, or 10 to 50 µL of peripheral blood is generally sufficient. For purified DNA, 50 to 100 ng is recommended for qPCR and sequencing, while ddPCR can be performed with as little as 10 to 20 ng of input DNA.
What is the typical turnaround time?
Standard genotyping by AS-PCR is usually completed within 3 to 5 working days after sample receipt. Quantitative VAF analysis by qPCR or ddPCR, and confirmatory Sanger sequencing, typically require 5 to 7 working days. NGS-based testing may require 10 to 15 working days depending on panel size and sequencing depth.
Can the test distinguish heterozygous from homozygous mutant mice?
Yes. Allele-specific PCR and quantitative methods accurately distinguish WT/WT, WT/V617F, and V617F/V617F genotypes. Precise VAF values near 50% indicate heterozygosity, whereas values approaching 100% indicate homozygosity or loss of heterozygosity, both of which are associated with more aggressive disease phenotypes.
How should samples be stored and shipped?
Fresh tissue can be stored at 4°C for up to 48 hours or frozen at -20°C or below for longer periods. Purified DNA should be eluted in TE buffer or nuclease-free water and shipped cold or frozen with ice packs. Avoid repeated freeze-thaw cycles, which degrade DNA quality and compromise quantitative accuracy.
Is the human JAK2 V617F mutation assay applicable to mouse models?
The mutation and surrounding sequence are highly conserved between human and mouse; however, assay primers and probes are typically designed against species-specific flanking sequences. For transgenic models expressing human JAK2, human-specific assays are used, whereas knock-in models carrying the murine Jak2 V617F allele require mouse-specific assays. Confirming the exact model design with the testing laboratory before submission is recommended.